

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 12, 2002, 10:46:59 ; Search time 16.3 Seconds
(without alignments)
424.444 Million cell updates/sec

Title: US-09-537-859b-2_COPY_28_99
Perfect score: 386
Sequence: 1 VSIPITCCFNVINRKIPIDR.....ERWVRDSMKHLDIFQNLKP 72

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283138 seqs, 96089334 residues

Number of hits satisfying chosen parameters: 283138

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: PIR.71.*

1: PIR1:*
2: PIR2:*
3: PIR3:*
4: PIR4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	382	99.0	99	2	JC5295	monocyte chemotact
2	277	71.8	99	2	JC2417	monocyte chemotact
3	270	69.9	97	2	JC4912	eotaxin precursor
4	249	64.5	99	2	A60299	monocyte chemotact
5	239	61.9	99	2	JC2136	monocyte chemotact
6	234	60.6	109	2	A54678	monocyte chemotact
7	219	56.7	96	2	I48099	eotaxin precursor
8	212	54.9	72	2	A55984	monocyte chemotact
9	212	54.9	96	2	JC2478	eotaxin precursor
10	211	54.7	148	1	A30209	PDGF-inducible JE
11	209	54.1	99	1	A39296	monocyte chemotact
12	209	54.1	99	2	JC2336	monocyte chemotact
13	209	54.1	125	2	I46857	monocyte chemotact
14	200	51.8	148	1	S07723	immediate-early se
15	190	49.2	120	2	I48147	monocyte chemotact
16	172.5	44.7	97	2	A48093	monocytic cytokine
17	149.5	38.7	93	2	B35673	LD78-beta protein
18	142.5	36.9	92	2	A30574	macrophage inflamm
19	138.5	35.9	92	1	A31767	macrophage inflamm
20	136.5	35.4	92	2	I46730	immune activation
21	130.5	33.8	92	2	C30552	macrophage inflamm
22	128	33.4	92	2	I53322	macrophage inflamm
23	128	33.2	92	2	A33393	macrophage inflamm
24	127.5	33.0	114	1	ETH0L	lymphotactin precu
25	121.5	31.5	91	1	A28815	monocyte chemotact
26	120	31.1	120	2	JE0177	lymphocyte and mon
27	118.5	30.7	114	1	ETMSL	lymphotactin precu
28	116.5	30.2	91	1	A46539	monocyte chemotact
29	114	29.5	96	2	A37236	I-309 protein prec

30	111	28.8	92	2	S24236	TCAS3 protein - mon
31	104	26.9	50	2	C60407	monocyte adherence
32	96	24.9	116	2	I49555	gene C10 protein -
33	85	22.0	101	2	S42496	interleukin-8 prec
34	85	22.0	103	2	A53096	interleukin-8 prec
35	79	20.5	95	2	U08841	interleukin-8 - do
36	77	19.9	101	2	I46871	interleukin-8 - ra
37	75	19.4	99	2	A37034	interleukin-8 prec
38	72	18.7	101	2	I48148	Neutrophil attract
39	71.5	18.5	117	2	B44253	alveolar macrophag
40	71.5	18.5	459	2	T44201	hypothetical prote
41	71.5	18.5	459	2	T44014	segment pp65/72k,
42	66	17.1	114	2	A55010	neutrophil-activat
43	66	17.1	132	2	A57325	C-X-C chemokine li
44	65	16.8	75	2	A54188	granulocyte chemot
45	65	16.8	93	2	G01540	cytokine SDF-1-bet

ALIGNMENTS

RESULT 1
JC5295
monocyte chemotactic protein-2 precursor - human
C:Species: Homo sapiens (man)
C:Date: 02-May-1997 #sequence_revision 18-Jul-1997 #text_change 20-Jun-2000
C:Accession: JC5295
R:Van Collie, E.; Froyen, G.; Nomiya, H.; Miura, R.; Fiten, P.; Van Aelst, I.; Van Blochem, Biophys. Res. Commun. 231, 726-730, 1997
A:Title: Human monocyte chemotactic protein-2: cDNA cloning and regulated expression
A:Reference number: JC5295; MID:97224420
A:Accession: JC5295
A:Molecule type: mRNA
A:Residues: 1-99 <VAN>
A:Cross-references: GB:Y10802; NID:q1924937; PID:CAA71760.1; PID:q1924938
A:Experimental source: GB: bone marrow
C:Comment: This protein belongs to the beta-chemokine family which is one of the major ligands and in tumor biology, and contribute to the trafficking and recruitment of the res
C:Genetics:
A:Gene: mcp-2
C:Superfamily: macrophage inflammatory protein
F:1-23/Domain: signal sequence #status predicted <Sig>
F:24-99/Product: monocyte chemotactic protein-2 #status predicted <Mat>

Query Match 99.0%; Score 382; DB 2; Length 99;
Best Local Similarity 98.6%; Pred. No. 8.4e-37;
Matches 71; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 VSIPITCCFNVINRKIPIDRLESTYRTINIQPKREAVIFKTKRGKVCADPKERWRDSM 60
DB 28 VSIPITCCFNVINRKIPIDRLESTYRTINIQPKREAVIFKTKRGKVCADPKERWRDSM 87

OY 61 KHLDDIFQNLKP 72
DB 88 KHLDDIFQNLKP 99

RESULT 2
JC2417
monocyte chemotactant protein-2 precursor - pig
C:Species: Sus scrofa domestica (domestic pig)
C:Date: 24-Feb-1995 #sequence_revision 24-Feb-1995 #text_change 16-Jul-1999
C:Accession: JC2417
R:Hosang, K.; Kroke, I.; Klaudiny, J.; Wempe, F.; Wutke, W.; Scheit, K.H.
Biochem. Biophys. Res. Commun. 205, 148-153, 1994
A:Title: Porcine luteal cells express monocyte chemotactant protein-2 (MCP-2): Ana
A:Reference number: JC2417; MID:95091716
A:Accession: JC2417
A:Molecule type: mRNA
A:Residues: 1-99 <HOS>
A:Cross-references: GB:Z48480; NID:q683718; PID:CAA8371.1; PID:q683719
A:Experimental source: corpus luteum

C:Superfamily: macrophage inflammatory protein
 F:1-23/Domain: signal sequence #status predicted <SIG>
 F:24-99/Product: monocyte chemoattractant protein-2 #status predicted <MAT>

Query Match 71.8%; Score 277; DB 2; Length 99;
 Best Local Similarity 70.8%; Pred. No. 1e-24;

Matches 51; Conservative 10; Mismatches 11; Indels 0; Gaps 0;

1 VSIPICCFNVINRKIPRIORLESTYRITNIOCPKAVIFKTKRGKVCADPKERWVDSM 60
 Db 28 VSIPICCFNVINRKIPRIORLESTYRITNIOCPKAVIFKTKRGKVCADPKERWVDSM 87

61 KHLDOIFONLKP 72
 Db 88 KHLDOIFONLKP 99

RESULT 3

12
 C:kin precursor - human

C:Species: Homo sapiens (man)
 C:Date: 01-Nov-1996 #sequence_revision 01-Nov-1996 #text_change 20-Jun-2000
 C:Accession: J04912

R:Barrels, J.; Schluter, C.; Richter, E.; Noso, N.; Kulke, R.; Christophers, E.; Schroe

Biochem. Biophys. Res. Commun. 225, 1045-1051, 1996
 A:Title: Human dermal fibroblasts express eotaxin: Molecular cloning, mRNA expression, &

A:Reference number: J04912; MUID:96374440

A:Accession: J04912

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-97 <BAR>

A:Cross-references: EMBL:Z75668; NID:91531982; PIDN:CAA9997.1; PID:91531983

A:Experimental source: dermal fibroblast

C:Comment: This protein has eosinophil specific chemotactic activity.

C:Superfamily: macrophage inflammatory protein

C:Keywords: fibroblast

F:1-18/Domain: signal sequence #status predicted <SIG>
 F:19-97/Product: eotaxin #status predicted <MAT>

Query Match 69.9%; Score 270; DB 2; Length 97;
 Best Local Similarity 67.6%; Pred. No. 6.3e-24;
 Matches 48; Conservative 12; Mismatches 11; Indels 0; Gaps 0;

2 SIPTCCFNVINRKIPRIORLESTYRITNIOCPKAVIFKTKRGKVCADPKERWVDSM 61
 Db 27 SVPTCCFNVINRKIPRIORLESTYRITNIOCPKAVIFKTKRGKVCADPKERWVDSM 86

62 HLDQIFONLKP 72
 Db 87 YLDQKSPKPK 97

RESULT 4
 monocyte chemoattractant protein 1 precursor - human

N:Alternate names: GDF-1; glioma-derived monocyte chemotactic factor 1; MCAF; MCP-1; mcf

C:Species: Homo sapiens (man)

C:Date: 20-Feb-1993 #sequence_revision 20-Feb-1993 #text_change 16-Jul-1999
 C:Accession: A33474; A33476; S03339; I51841; A60299; A32300; A32396; A34561; I57488; JCI

R:Shyy, Y.J.; Li, Y.S.; Kolattukudy, P.E.
 Biochem. Biophys. Res. Commun. 169, 346-351, 1990
 A:Title: Structure of human monocyte chemotactic protein gene and its regulation by TPA.
 A:Reference number: A33474; MUID:90290466
 A:Accession: A33474
 A:Molecule type: DNA
 A:Residues: 1-99 <SHY>
 A:Cross-references: GB:M37719; NID:9187447; PIDN:AAA18102.1; PID:g487124
 R:Rollins, B.J.; Stier, P.; Ernst, T.; Wong, G.G.
 Mol. Cell. Biol. 9, 4687-4695, 1989
 A:Title: The human homolog of the JE gene encodes a monocyte secretory protein.

A:Reference number: A33476; MUID:90097880

A:Accession: A33476

A:Molecule type: mRNA

A:Residues: 1-99 <ROD>

A:Cross-references: GB:M30816; GB:M31625; GB:M31626; NID:9188701; PIDN:AAA6330.1; PI

R:Yoshimura, T.; Yuhki, N.; Moore, S.K.; Appella, E.; Lerman, M.I.; Leonard, E.J.
 FEBS Lett. 244, 487-493, 1989

A:Title: Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning,

A:Reference number: S03339; MUID:89155605

A:Accession: S03339

A:Status: not compared with conceptual translation

A:Molecule type: mRNA

A:Residues: 1-99 <YOS>

A:Cross-references: GB:X14768; NID:934513; PIDN:CAA32876.1; PID:g34514

A:Experimental source: glioma cell line U-105MG

R:Yoshimura, T.; Leonard, E.J.
 Adv. Exp. Med. Biol. 305, 47-56, 1991

A:Title: Human monocyte chemoattractant protein-1 (MCP-1).

A:Reference number: I51841; MUID:92095166

A:Accession: I51841

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-99 <YOS>

A:Cross-references: GB:S71513; NID:g240867; PIDN:AA820651.1; PID:g240868

R:Botazzi, B.; Colotta, F.; Sica, A.; Nobili, N.; Mantovani, A.
 Int. J. Cancer 45, 795-797, 1990

A:Title: A chemoattractant expressed in human sarcoma cells (tumor-derived chemotacti

-1/MCAF).

A:Reference number: A60299; MUID:90216082

A:Accession: A60299

A:Status: not compared with conceptual translation

A:Molecule type: mRNA

A:Residues: 1-99 <BOF>

R:Furutani, Y.; Nomura, H.; Notake, M.; Oyama, Y.; Fukui, T.; Yamada, M.; Larsen, C

Biochem. Biophys. Res. Commun. 159, 249-255, 1989

A:Title: Cloning and sequencing of the cDNA for human monocyte chemotactic and activa

A:Reference number: A32300; MUID:89165862

A:Accession: A32300

A:Status: not compared with conceptual translation

A:Molecule type: protein

A:Residues: 1-99 <FUR>

A:Cross-references: GB:M24545; NID:9187434; PIDN:AAA18164.1; PID:g307163

R:Robinson, E.A.; Yoshimura, T.; Leonard, E.J.; Tanaka, S.; Griffin, P.R.; Shabanowitz

Proc. Natl. Acad. Sci. U.S.A. 86, 1850-1854, 1989

A:Title: Complete amino acid sequence of a human monocyte chemoattractant, a putative

A:Reference number: A32396; MUID:89184525

A:Accession: A32396

A:Molecule type: protein

A:Residues: X, 25-99 <ROB>

R:Decock, B.; Conings, R.; Lenaerts, J.P.; Billiau, A.; Van Damme, J.

Biochem. Biophys. Res. Commun. 167, 904-909, 1990

A:Title: Identification of the monocyte chemotactic protein from human osteosarcoma c

A:Reference number: A34561; MUID:90211336

A:Accession: A34561

A:Molecule type: protein

A:Residues: 29-33, XX, 36-52, 82-92 <DEC>

R:Li, Y.S.; Shyy, Y.J.; Wright, J.G.; Valente, A.J.; Cornhill, J.F.; Kolattukudy, P.E

Mol. Cell. Biochem. 126, 61-68, 1993

A:Title: The expression of monocyte chemotactic protein (MCP-1) in human vascular end

A:Reference number: I57488; MUID:94150478

A:Accession: I57488

A:Status: translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-99 <LTY>

A:Cross-references: GB:S69738; NID:9545464; PIDN:AA82926.1; PID:9545465

R:Ye, Q.N.; Su, G.F.; Yuan, Y.; Huang, C.F.

Chinese J. Microbiol. Immunol. 14, 29-32, 1994

A:Title: The PCR, cloning and sequencing of human monocyte chemoattractant protein-1

A:Reference number: JCI096

A:Accession: JCI096

A:Molecule type: mRNA

A:Residues: 24-28, Q, 30-99 <YEO>

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 12, 2002, 10:48:00 ; Search time 11.92 seconds

(without alignments)
233.876 Million cell updates/sec

Title: US-09-537-859b-2_COPY_28_99

Perfect score: 366

Sequence: 1 VSIPITCCFVNNKIPIDR.....ERWVDSMKHLDFQNLKP 72

Scoring table: BIOSUM62

Gapop 10.0, Gapext 0.5

Searched: 105224 seqs, 38719550 residues

Tc: number of hits satisfying chosen parameters: 105224

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

SUMMARIES

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	ID	Description
1	386	100.0	99	1 SY08_HUMAN	P80075 homo sapien
2	277	71.8	99	1 SY08_PIG	P49873 sus scrofa
3	267	69.2	97	1 E07A_HUMAN	P51671 homo sapien
4	259	67.1	99	1 SY08_BOVIN	O09141 bos taurus
5	258	66.8	99	1 SY02_MACFA	O09474 macaca fasc
6	249	64.5	99	1 SY02_HUMAN	P13500 homo sapien
7	241	62.4	104	1 SY12_MOUSE	O62401 mus musculu
8	239	61.9	99	1 SY02_PIG	P42831 sus scrofa
9	235	61.9	101	1 SY02_CANFA	P52203 canis famil
10	235	60.9	97	1 E07A_RAT	P97545 rattus norv
11	234	60.6	99	1 SY07_HUMAN	P80098 homo sapien
12	232	60.1	74	1 MCPB_BOVIN	P80343 bos taurus
13	229	59.3	97	1 E07A_MOUSE	P48298 mus musculu
14	220	57.0	97	1 SY08_MOUSE	O92121 mus musculu
15	219	56.7	96	1 E07A_CAVPO	P80325 cavia porce
16	216.5	56.1	98	1 SY13_HUMAN	O09616 homo sapien
17	211	54.7	98	1 SY02_MOUSE	P10148 mus musculu
18	209	54.1	99	1 MCPA_BOVIN	P28291 bos taurus
19	209	54.1	125	1 SY02_RABIT	P28292 oryctolagus
20	200	51.8	148	1 SY02_RAT	P14844 rattus norv
21	190	49.2	120	1 SY02_CAVPO	O00872 cavia porce
22	177.5	46.0	97	1 SY07_MOUSE	O03366 mus musculu
23	175.5	45.5	97	1 SY07_RAT	O09398 rattus norv
24	164.5	42.6	70	1 REGI_BOVIN	P82943 bos taurus
25	155.5	40.3	90	1 SY04_CHICK	O90826 gallus gall
26	155	40.2	119	1 SY24_MOUSE	O01175 mus musculu
27	153	39.6	119	1 SY14_HUMAN	O16627 homo sapien
28	149.5	38.7	93	1 SY14_HUMAN	O16619 homo sapien
29	149.5	38.7	93	1 SY13_HUMAN	P10147 homo sapien
30	142.5	36.9	92	1 SY03_HUMAN	P13236 h small ind
31	138.5	35.9	92	1 SY04_HUMAN	P46632 oryctolagus
32	136.5	35.4	92	1 SY04_RABIT	O55145 rattus norv
33	132.5	34.3	393	1 SYD1_RAT	

ALIGNMENTS

34	131.5	34.1	92	1 SY04_RAT	P50230 rattus norv
35	131.5	34.1	397	1 SYD1_HUMAN	P78427 homo sapien
36	130.5	33.8	92	1 SY04_MOUSE	P14097 mus musculu
37	129	33.4	92	1 SY03_RAT	P50229 rattus norv
38	128	33.2	92	1 SY03_MOUSE	P10855 mus musculu
39	127.5	33.0	94	1 SY26_HUMAN	O99258 homo sapien
40	127.5	33.0	114	1 SYC1_HUMAN	P47922 homo sapien
41	127.5	33.0	114	1 SYC2_HUMAN	O99433 homo sapien
42	125.5	32.5	395	1 SYD1_MOUSE	O35188 mus musculu
43	124.5	32.3	91	1 SY05_CAVPO	P97272 cavia porce
44	123.5	32.0	89	1 SY18_HUMAN	P55774 h small ind
45	123.5	32.0	113	1 SY15_HUMAN	O16663 homo sapien

RESULT 1
SY08_HUMAN STANDARD; PRT; 99 AA.

AC P80075; P78388;
DT 01-DEC-1992 (Rel. 24, Created)

DT 01-NOV-1997 (Rel. 35, Last sequence update)

DT 16-OCT-2001 (Rel. 40, Last annotation update)

DE Small, inducible cytokine A8 precursor (Monocyte chemoattractant protein 2) (HC14).

DE (MCP-2) (Monocyte chemoattractant protein 2) (HC14).

GN SCYA8 OR SCYA10 OR MCP2.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

NCBI_TaxID=9606;

[1]
SEQUENCE FROM N.A., AND VARIANT GLN-69.

RX MEDLINE=97237052; PubMed=9119400.

RA van Damme J., Fiten P., Nomiya H., Sakaki Y., Miura R., Yoshie O.,

van Damme J., Opdenakker G.;
"The human MCP-2 gene (SCYA8): cloning, sequence analysis, tissue

expression, and assignment to the CC chemokine gene contig on

RT chromosome 17q11.2.";

RL Genomics 40:323-331(1997).

[2]
SEQUENCE FROM N.A., AND VARIANT GLN-69.

RX MEDLINE=91207938; PubMed=2518726;

RA Chang H.C., Hsu F., Freeman G.J., Griffin J.D., Reinherz E.L.;

RT "Cloning and expression of a gamma-interferon-inducible gene in

monocytes: a new member of a cytokine gene family.";

Int. Immunol. 1:388-399(1989).

[4]
SEQUENCE OF 26-99.

RX MEDLINE=92308855; PubMed=1613466;

RA van Damme J., Proost P., Lenaerts J.-P., Opdenakker G.;

RT "Structural and functional identification of two human, tumor-derived

monocyte chemoattractant proteins (MCP-2 and MCP-3) belonging to the

chemokine family.";

J. Exp. Med. 176:59-65(1992).

[5]
SUBUNIT.

RX MEDLINE=97053697; PubMed=8898111;

RA Kim K.-S., Rajaratnam K., Clark-Lewis I., Sykes B.D.;

RT "Structural characterization of a monomeric chemokine: monocyte

chemoattractant protein-3.";

FEBS Lett. 395:277-282(1996).

-!- FUNCTION: CHEMOTACTIC FACTOR THAT ATTRACTS MONOCYTES, LYMPHOCYTES,

CC BASOPHILS AND EOSINOPHILS. MAY PLAY A ROLE IN NEOPLASIA AND
 CC INFLAMMATORY HOST RESPONSES. THIS PROTEIN CAN BIND HEPARIN.
 CC -1- SUBUNIT: MONOMER OR HOMODIMER; IN EQUILIBRIUM.
 CC -1- TISSUE SPECIFICITY: HIGHEST EXPRESSION FOUND IN THE SMALL
 CC INTESTINE AND PERIPHERAL BLOOD CELLS. INTERMEDIATE LEVELS SEEN IN
 CC THE HEART, PLACENTA, LUNG, SKELETAL MUSCLE, THYMUS, COLON, OVARY,
 CC SPINAL CORD AND PANCREAS. LOW LEVELS SEEN IN THE BRAIN, LIVER,
 CC SPLEEN AND PROSTATE.
 CC -1- INDUCTION: BY INTERFERON GAMMA, MITOGENS AND INTERLEUKIN-1.
 CC -1- SIMILARITY: BELONGS TO THE INTERCRINE BETA FAMILY (SMALL CYTOKINE
 CC C-C) (CHEMOKINE CC).
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: X99886; CAA68168.1; ALT_INIT.
 DR EMBL: Y10802; CAA71760.1; -
 DR EMBL: Y16645; CAA76341.1; -
 DR HSSP: P51671; LEOT.
 DR MIM: 602283; -
 DR InterPro: IPR001811; Chemokine_IL8.
 DR InterPro: IPR000827; Small_cytokine_CC.
 DR Pfam: PF00048; IL8; 1.
 DR SMART: SM00199; SCY; 1.
 DR PROSITE: PS00472; SMALL_CYTOKINES_CC; 1.
 DR Cytokine; Chemotaxis; Signal; Heparin-binding; Inflammatory response;
 KW Polymorphism.
 FT SIGNAL 1 23 PROBABLE.
 FT CHAIN 24 99 SMALL INDUCIBLE CYTOKINE A8.
 FT MOD_RES 24 24 PYRROLIDONE CARBOXYLIC ACID.
 FT DISULFID 34 59 BY SIMILARITY.
 FT DISULFID 35 75 BY SIMILARITY.
 FT VARIANT 69 69 K->Q.
 FT /FTID=VAR_001633.
 FT SEQUENCE 99 AA; 11246 MW; 9D67976BB9422P2A CRC64;
 SO
 Query Match 100.0%; Score 386; DB 1; Length 99;
 Best Local Similarity 100.0%; Pred. No. 1.2e-38;
 Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 VSIPITCCFNVIKRIPIORLESYTRITNIQCPEAVIFKTKRGKVCADPKERWRDSDM 60
 28 VSIPITCCFNVIKRIPIORLESYTRITNIQCPEAVIFKTKRGKVCADPKERWRDSDM 87
 QY 61 KHLDOIFONLKP 72
 88 KHLDOIFONLKP 99
 DB
 RESULT 2
 ID SY08_PIG STANDARD: PRT; 99 AA.
 AC P49873;
 DT 01-OCT-1996 (Rel. 34, Created)
 DT 01-OCT-1996 (Rel. 34, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE Small inducible cytokine A8 precursor (Monocyte chemotactic protein 2)
 DE (MCP-2) (Monocyte chemoattractant protein 2).
 GN SCY8 OR MCP2.
 OS Sus scrofa (Pig).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
 OC NCBI_Taxid=9823;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=95091716; PubMed=799015;
 RA Hosang K.K., Knoke I.I., Klaudiny J.J., Wempe F.F., Wutke W.W.,

RA Scheit K.K.;
 RT "Porcine luteal cells express monocyte chemoattractant protein-2
 RT (MCP-2): analysis by cDNA cloning and northern analysis."
 RL Biochem. Biophys. Res. Commun. 205:148-153(1994).
 CC -1- FUNCTION: CHEMOTACTIC FACTOR THAT ATTRACTS MONOCYTES. THIS PROTEIN
 CC CAN BIND HEPARIN.
 CC -1- SUBUNIT: MONOMER OR HOMODIMER; IN EQUILIBRIUM (BY SIMILARITY).
 CC -1- SIMILARITY: BELONGS TO THE INTERCRINE BETA FAMILY (SMALL CYTOKINE
 CC C-C) (CHEMOKINE CC).
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: Z48480; CAA88371.1; -
 DR HSSP: P51671; LEOT.
 DR InterPro: IPR001811; Chemokine_IL8.
 DR InterPro: IPR000827; Small_cytokine_CC.
 DR Pfam: PF00048; IL8; 1.
 DR SMART: SM00199; SCY; 1.
 DR PROSITE: PS00472; SMALL_CYTOKINES_CC; 1.
 DR Cytokine; Chemotaxis; Signal; Heparin-binding; Inflammatory response;
 FT SIGNAL 1 23 BY SIMILARITY.
 FT CHAIN 24 99 PYRROLIDONE CARBOXYLIC ACID (BY
 FT MOD_RES 24 24 SIMILARITY).
 FT DISULFID 34 59 SMALL INDUCIBLE CYTOKINE A8.
 FT DISULFID 35 75 BY SIMILARITY.
 FT SEQUENCE 99 AA; 10903 MW; D3DA0F7A964CDB1 CRC64;
 SO
 Query Match 71.8%; Score 277; DB 1; Length 99;
 Best Local Similarity 70.8%; Pred. No. 7.7e-26;
 Matches 51; Conservative 10; Mismatches 11; Indels 0; Gaps 0;
 QY 1 VSIPITCCFNVIKRIPIORLESYTRITNIQCPEAVIFKTKRGKVCADPKERWRDSDM 60
 28 VSIPITCCFNVIKRIPIORLESYTRITNIQCPEAVIFKTKRGKVCADPKERWRDSDM 87
 QY 61 KHLDOIFONLKP 72
 88 KHLDOIFONLKP 99
 DB
 RESULT 3
 ID E0TA_HUMAN STANDARD: PRT; 97 AA.
 AC P51671; P50877; Q92490; Q92491;
 DT 01-OCT-1996 (Rel. 34, Created)
 DT 01-OCT-1996 (Rel. 34, Last sequence update)
 DT 01-MAR-2002 (Rel. 41, Last annotation update)
 DE Eotaxin precursor (Eosinophil chemotactic protein).
 GN SCY11.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 OC NCBI_Taxid=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=96181758; PubMed=8597956;
 RA Garcia-Zepeda E.A., Rothenberg M.E., Ownbey T.R., Leder P.,
 RA Luster A.D.;
 RT "Human eotaxin is a specific chemoattractant for eosinophil cells and
 RT provides a new mechanism to explain tissue eosinophilia."
 RL Nat. Med. 2:449-456(1996).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=96189937; PubMed=8609214;
 RA Ponath P.D., Qin S., Ringler D.J., Clark-Lewis I., Wang J., Kassam N.,

OY	1	VSPITCCFVIVIRKIPIDRLSYRPIQOCPEAVLFEIKRKGEVCADPKERWSDM	60
		:	
Dd	29	VSPRIQCCEVINGKIPEKKDSYTRITNSOCPDAVLFTKRADRYCADPKQAMVTSTI	80
OY	61	KHLDOIFONLKP	72
		: :	
Dd	89	RLLDOKSRTPKP	100
RESULT O9TTO4	2	PRELIMINARY:	PRT: 100 AA.
ID	O9TTO4		

AC 09T04;
 DT 01-MAY-2000 (TReMBLrel. 13, Created)
 DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)
 DT 01-DEC-2001 (TReMBLrel. 19, Last annotation update)
 DE EOTAXIN PRECURSOR.
 OS Equus caballus (Horse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Perissodactyla; Equidae; Equus.
 OX NCBI_TaxID=9796;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21061912; PubMed=11044560;
 RA Benarafa C., Cunningham F.M., Hamblin A.S., Horohov D.W.,
 RA Collins M.E.;
 RT "Cloning of equine chemokines eotaxin, monocyte chemoattractant
 protein (MCP)-1, MCP-2 and MCP-4, mRNA expression in tissues and
 induction by IL-4 in dermal fibroblasts."
 RL Vet. Immunol. Immunopathol. 76:283-298(2000).
 DR EMBL; AJ251188; CAB61624.1; -.
 DR HSSP; P51671; IEOT.
 DR InterPro; IPR001811; Chemokine_IL8.
 DR Pfam; PF00048; IL8; 1.
 DR SMART; SM00199; SCY; 1.
 DR PROSITE; PS00472; SMALL_CYTOKINES_CC; 1.
 DR SIGNAL.
 KW SIGNAL.
 FT CHAIN 1 23 POTENTIAL.
 FT SIGNAL 24 100 EOTAXIN.
 SQ SEQUENCE 100 AA; 11247 MW; 11F08EC00E75D50B CRC64;

Query Match 61.4%; Score 237; DB 6; Length 100;
 Best Local Similarity 61.5%; Pred. No. 4.2e-21;
 Matches 40; Conservative 16; Mismatches 9; Indels 0; Gaps 0;

QY 1 VSIPITCCFNVINRKIPQRLSEYTRITNIOCPKEAVYFKTKRGKVCADPKERNVRSKM 60
 DB 26 VSISTVCCFNVASRKISFQRLSYRTKITSCKPQKAVIFKTKQAKKICADPKQKVVQDAM 85
 QY 61 KHLDD 65
 DB 86 KYLDE 90

RESULT 3
 Q9TTS6 PRELIMINARY; PRT; 97 AA.
 ID Q9TTS6;
 DT 01-MAY-2000 (TReMBLrel. 13, Created)
 DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)
 DT 01-JUN-2001 (TReMBLrel. 17, Last annotation update)
 DE EOTAXIN.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 OC Bovidae; Bovine; Bos.
 OX NCBI_TaxID=9913;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Vogel B., Klinder A., Aust G.;
 RT "Molecular cloning of bovine eotaxin mRNA."
 RL Submitted (FE8-1999) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AJ132003; CAB61617.1; -.
 DR HSSP; P51671; IEOT.
 DR InterPro; IPR001811; Chemokine_IL8.
 DR Pfam; PF00048; IL8; 1.
 DR SMART; SM00199; SCY; 1.
 SQ SEQUENCE 97 AA; 10965 MW; 9E65F23E1DDEB743 CRC64;

Query Match 58.0%; Score 224; DB 6; Length 97;
 Best Local Similarity 54.3%; Pred. No. 1.5e-19;
 Matches 38; Conservative 19; Mismatches 13; Indels 0; Gaps 0;

QY 2 SIPIITCCFNVINRKIPQRLSEYTRITNIOCPKEAVYFKTKRGKVCADPKERNVRSKM 61
 DB 27 SIPIITCCFNVASRKISFQRLSYRTKITSCKPQKAVIFKTKQAKKICADPKQKVVQDAM 86
 QY 62 HLDQIFQNLK 71
 DB 87 YLNDKSGTLK 96

RESULT 4
 Q9TTO2 PRELIMINARY; PRT; 81 AA.
 ID Q9TTO2;
 DT 01-MAY-2000 (TReMBLrel. 13, Created)
 DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)
 DT 01-DEC-2001 (TReMBLrel. 19, Last annotation update)
 DE MONOCYTE CHEMOATTRACTANT PROTEIN-2 PRECURSOR (FRAGMENT).
 GN MCP-2.
 OS Equus caballus (Horse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Perissodactyla; Equidae; Equus.
 OX NCBI_TaxID=9796;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21061912; PubMed=11044560;
 RA Benarafa C., Cunningham F.M., Hamblin A.S., Horohov D.W.,
 RA Collins M.E.;
 RT "Cloning of equine chemokines eotaxin, monocyte chemoattractant
 protein (MCP)-1, MCP-2 and MCP-4, mRNA expression in tissues and
 induction by IL-4 in dermal fibroblasts."
 RL Vet. Immunol. Immunopathol. 76:283-298(2000).
 DR EMBL; AJ251190; CAB61626.1; -.
 DR HSSP; P13500; IDOK.
 DR InterPro; IPR001811; Chemokine_IL8.
 DR Pfam; PF00048; IL8; 1.
 DR SMART; SM00199; SCY; 1.
 DR SIGNAL.
 KW SIGNAL.
 FT CHAIN 1 23 POTENTIAL.
 FT SIGNAL 24 >81 BY SIMILARITY.
 FT NON_TER 81 81
 SQ SEQUENCE 81 AA; 8838 MW; A34ADE103C386B0F CRC64;

Query Match 57.5%; Score 222; DB 6; Length 81;
 Best Local Similarity 72.2%; Pred. No. 2.2e-19;
 Matches 39; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

QY 1 VSIPITCCFNVINRKIPQRLSEYTRITNIOCPKEAVYFKTKRGKVCADPKER 54
 DB 28 VSIPITCCFNVAKKVPQRLSEYTRITSOCSEAVYFKTKVDKICADPKKK 81

RESULT 5
 Q9TTO3 PRELIMINARY; PRT; 99 AA.
 ID Q9TTO3;
 DT 01-MAY-2000 (TReMBLrel. 13, Created)
 DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)
 DT 01-DEC-2001 (TReMBLrel. 19, Last annotation update)
 DE MONOCYTE CHEMOATTRACTANT PROTEIN-1 PRECURSOR.
 GN MCP-1.
 OS Equus caballus (Horse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Perissodactyla; Equidae; Equus.
 OX NCBI_TaxID=9796;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21061912; PubMed=11044560;
 RA Benarafa C., Cunningham F.M., Hamblin A.S., Horohov D.W.,
 RA Collins M.E.;

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 12, 2002, 10:46:59 ; Search time 30.03 Seconds
(without alignments)
266.311 Million cell updates/sec

Title: US-09-537-859B-2_COPY_28_99

Perfect score: 386
Sequence: 1 VSIPITCFNVIINKRIPQR.....ERWRDSMKHLDJFONLRP 72

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues

number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_032802.*
1: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1980.DAT.*
2: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1981.DAT.*
3: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1982.DAT.*
4: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1983.DAT.*
5: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1984.DAT.*
6: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1985.DAT.*
7: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1986.DAT.*
8: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1987.DAT.*
9: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1988.DAT.*
10: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1989.DAT.*
11: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1990.DAT.*
12: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1991.DAT.*
13: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1992.DAT.*
14: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1993.DAT.*
15: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1994.DAT.*
16: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1995.DAT.*
17: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1996.DAT.*
18: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1997.DAT.*
19: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1998.DAT.*
20: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA1999.DAT.*
21: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA2000.DAT.*
22: /SIDSI/gcgdata/hold-geneeq/geneeqp-emb1/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	386	100.0	76	21	AA199031
2	386	100.0	77	21	AA19786
3	386	100.0	99	20	AA190300
4	386	100.0	99	20	AA197233
5	386	100.0	99	20	AA197237
6	386	100.0	109	19	AA197234
7	386	99.0	71	20	AA197234
8	382	99.0	71	20	AA197238
9	382	99.0	109	18	AA197238
10	363	94.0	77	20	AA197238
11	348	90.2	72	16	AA197238

12	267	69.2	74	21	AA199023
13	267	69.2	97	17	AA199067
14	267	69.2	97	18	AA199090
15	267	69.2	97	18	AA199099
16	267	69.2	97	21	AA199099
17	267	69.2	323	21	AA199058
18	267	69.2	325	21	AA199058
19	267	69.2	330	21	AA199060
20	249	64.5	76	10	AA199029
21	249	64.5	76	13	AA199029
22	249	64.5	76	16	AA199029
23	249	64.5	76	16	AA199029
24	249	64.5	76	17	AA199029
25	249	64.5	76	18	AA199029
26	249	64.5	76	19	AA199029
27	249	64.5	76	21	AA199029
28	249	64.5	76	21	AA199030
29	249	64.5	77	16	AA199030
30	249	64.5	99	10	AA199030
31	249	64.5	99	13	AA199030
32	249	64.5	99	16	AA199030
33	249	64.5	99	16	AA199030
34	249	64.5	99	19	AA199030
35	249	64.5	99	20	AA199030
36	249	64.5	99	20	AA199030
37	249	64.5	99	21	AA199030
38	249	64.5	99	22	AA199030
39	249	64.5	99	22	AA199030
40	249	64.5	99	22	AA199030
41	249	64.5	99	22	AA199030
42	249	64.5	99	22	AA199030
43	249	64.5	99	22	AA199030
44	249	64.5	99	22	AA199030
45	249	64.5	99	22	AA199030

ALIGNMENTS

RESULT 1	AA199031	standard; protein; 76 AA.
ID	AA199031	
AC	AA199031	
DT	30-MAY-2000	(first entry)
DE	Amino acid sequence of chemokine receptor ligand MCP-2.	
XX	Chemokine receptor; ligand; inflammatory response; immune effector cell;	
XX	secondary tissue damage; central nervous system injury; MCP-2;	
XX	CNS inflammatory disease; neurodegenerative disorder; heart disease;	
XX	inflammatory eye disease; inflammatory bowel disease;	
XX	inflammatory joint disease; inflammatory kidney; renal disease;	
XX	inflammatory lung disease; inflammatory nasal disease;	
XX	inflammatory thyroid disease; thyroiditis; cytokine-regulated cancer.	
XX	Homo sapiens.	
XX	WO200004926-A2.	
XX	03-FEB-2000.	
XX	21-JUL-1999; 99WO-CA00659.	
XX	22-JUL-1998; 98US-0120523.	
XX	(OSPR-) OSPREY PHARM LTD.	
XX	McDonald JR, Coggin PJ;	
XX	WPI: 2000-182542/16.	

PT A new therapeutic agent comprising a conjugate for treating secondary
PT tissue damage and other disease conditions like Alzheimer's disease,
PT stroke, Parkinson's disease and atherosclerosis
XX
XX
PS Disclosure: Page 60; 204pp; English.

CC The present sequence represents a chemokine receptor ligand. The present
CC ligand can be incorporated into the conjugates of the invention. The
CC specification describes a conjugate, comprising a targeted agent and a
CC chemokine receptor ligand. The conjugate binds to a chemokine receptor
CC resulting in internalisation of the targeted agent in cells bearing the
CC receptor. The conjugates are used for formulating a medicament or for
CC treating disorders associated with inflammatory responses resulting from
CC activation, proliferation and migration of immune effector cells. The
CC disorders or disease states comprise secondary tissue damage such as
CC central nervous system (CNS) injury, CNS inflammatory diseases,
CC neurodegenerative disorders, heart disease, inflammatory eye diseases,
CC inflammatory bowel diseases, inflammatory joint diseases, inflammatory
CC kidney or renal diseases, inflammatory lung diseases, inflammatory
CC nasal diseases, inflammatory thyroid disease such as thyroiditis, or
XX cytokine-regulated cancers.

SQ Sequence 76 AA:

Query Match 100.0%; Score 386; DB 21; Length 76;
Best Local Similarity 100.0%; Pred. No. 6e-39;
Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 VSIPITCCFNVINRKIPRIORLESTYRTITNIOCPKEAVIFKTRGKEVCADPKERWVDSM 60
Db 5 vsipitccfnvinrkikiprioriesyrtitnigcpkeavifktrgkvcadpkerwvrdsm 64
|||||
OY 61 KHLDOIIFONLKP 72
|||||

Db 65 khlqdlfgnlkp 76

RESULT 2

AAB15786
ID AAB15786 standard; Protein; 77 AA.

AC AAB15786;

DT 17-JAN-2001 (first entry)

DE Human chemokine MCP-2 SEQ ID NO: 17.

XX Macrophage recruitment; chemokine derivative; MCP-1; osteoporosis;
XX monocyte chemoattractant protein-1; inflammation; atherosclerosis; HIV;
KM AIDS; stroke; psoriasis; autoimmune disease; hypertension; endotoxaemia;
KM basophil-mediated disease; myocardial infarction; acute ischaemia;
KM rheumatoid arthritis; contraception.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Misc-difference 47 /note="encoded by CAA"

XX MO200042071-A2.

XX 20-JUL-2000.

XX 12-JAN-2000; 2000MO-US00821.

XX 12-JAN-1999; 99US-0229071.

XX 17-MAR-1999; 99US-0271192.

XX 01-DEC-1999; 99US-0452406.

XX (NEOR-) NEORX CORP.

XX Grainger DJ, Tatalick LM;

XX WPI; 2000-499101/44.
DR N-PSDB; AAA74886.

PT New peptide 3, amide and heterocyclic compounds and saccharide
PT conjugates used for inhibiting chemokine induced activity and for
PT treating e.g. stroke, vascular diseases, autoimmune diseases and tumour
PT growth
XX
XX Example 1; Page 134; 387pp; English.

CC The present invention concerns the identification of a number of
CC chemokines which can be used to produce derivatives, agonists and
CC antagonists which are then useful in disease treatment. The chemokines
CC include sequences AAB15785-B15794, AAB15803-B15813 and AAB15831-B15848.
CC These chemokine derivatives can be used to treat diseases such as
CC autoimmune diseases, atherosclerosis, osteoporosis, HIV infection and
CC AIDS, psoriasis, inflammatory diseases, hypertension, basophil-mediated
CC rheumatoid arthritis, and can be used to prevent strokes and as
CC contraceptives. The coding sequences for the chemokines can be used in
CC gene therapy for the same diseases, as well as in the production of
CC animal models.

SQ Sequence 77 AA:

Query Match 100.0%; Score 386; DB 21; Length 77;
Best Local Similarity 100.0%; Pred. No. 6.1e-39;
Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 VSIPITCCFNVINRKIPRIORLESTYRTITNIOCPKEAVIFKTRGKEVCADPKERWVDSM 60
Db 6 vsipitccfnvinrkikiprioriesyrtitnigcpkeavifktrgkvcadpkerwvrdsm 65
|||||

OY 61 KHLDOIIFONLKP 72
|||||

Db 66 khlqdlfgnlkp 77

RESULT 3

AAV05300
ID AAV05300 standard; Protein; 99 AA.

AC AAV05300;

DT 25-JUN-1999 (first entry)

DE C-C chemokine, MCP2.

XX C-C chemokine; RANTES; MCP2; chemokine antagonist; inflammatory disease;
XX HIV infection; tumour; angiogenesis-related disease; autoimmune disease;
KM haematopoiesis-related disease; CD26/DPP IV; immune disease; diagnosis;
KM atherosclerosis; pulmonary disease; skin disorder; therapy.

OS Homo sapiens.

XX Key Location/Qualifiers

XX EP905240-A1.

XX 31-MAR-1999.

XX 19-DEC-1997; 97EP-0122471.

XX 29-SEP-1997; 97EP-0116863.

XX (ISTF) ARS APPLIED RES SYSTEMS HOLDING NV.

XX Proost P, Struyf S, Van Damme J;

XX WPI; 1999-216695/19.

XX New amino-terminally truncated C-C chemokines have antagonistic
PT activity, for treatment of immune, inflammatory and infectious

PT diseases

XX Claim 4; Fig 1; 30pp; English.

XX This sequence represents the C-C chemokine MCP2. The invention relates

CC to amino-terminally truncated C-C chemokines, having chemokine

CC antagonistic activity. The truncated chemokines are specifically

CC residues 26 to 91 of the RANTES sequence (see AA05299) or residues 29 to

CC 99 of the MCP2 sequence (this sequence). The new chemokines are useful

CC as medicaments, for diagnosis and/or treatment of diseases which require

CC antagonistic activity of a chemokine e.g. inflammatory diseases, HIV

CC infection, tumours, and angiogenesis- and hematopoiesis-related

CC diseases. The invention also relates to the use of CD26/DP IV for

CC treatment of inflammatory, immune and infectious diseases, including

CC autoimmune diseases, atherosclerosis, pulmonary diseases and skin

CC disorders.

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC truncated C-C chemokines, having chemokine antagonistic activity. The

CC new chemokines are useful as medicaments, for diagnosis and/or treatment

CC of diseases which require antagonistic activity of a chemokine e.g.

CC inflammatory diseases, HIV infection, tumours, and angiogenesis- and

CC hematopoiesis-related diseases, including auto-immune diseases,

CC atherosclerosis, pulmonary diseases and skin disorders.

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

Query Match 100.0%; Score 386; DB 20; Length 99;
 Best Local Similarity 100.0%; Pred. No. 8.2e-39;
 Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VSIPITCCFNVINRKIPIDRLSEYTRITNIOCPKEAVIFKTRGKVCADPKERVRDSM 60
 |||||
 Db 28 vsipitccfnvinrkikiprlslyrltnlqcpkeavifktrgkvcadpkervrds 87
 |||||
 QY 61 KHLDOIIFONLKP 72
 |||||
 Db 88 khlldqifgnlkp 99

RESULT 6

AAW42072
 ID AAW42072 standard; Protein: 109 AA.
 AC AAW42072;

09-JUN-1998 (first entry)

Human MC proprotein.

KW Human monocyte chemotactic proprotein; MCPP; Incyte clone; allergy;
 KW macrophage; diagnostic assay; body fluid; lung; biopsy;
 KW autoimmune disease; AIDS; asthma; rheumatoid arthritis; NIDDM;
 KW breast cancer; bladder.

OS Homo sapiens.

PN W09802459-A1.

PD 22-JAN-1998.

PF 15-JUL-1997; 97WO-US12349.

PR 15-JUL-1996; 96US-0683655.

PA (INCY-) INCYTE PHARM INC.

PI Au-Young J, Coleman R, Hillman JL;

DR WPI: 1998-110529/10.

DR N-PSDB; AAV09218.

PT New human monocyte chemotactic proprotein - has homology to CC
 chemokine(s) useful for identifying agent for treating auto-immune
 diseases or allergic responses

PS Claim 1; Pages 38-39; 53pp; English.

CC The is a human monocyte chemotactic proprotein sequence. Its cDNA was
 CC first identified in Incyte clone 965517 from a breast cDNA library.
 CC Antisense nucleotides can be used to control human MCPP expression.
 CC especially where it may lead to inappropriate monocyte or macrophage
 CC activity causing damage associated with allergic responses to organs
 CC such as the lungs. Antisense nucleotides and MCPP cDNA may be used
 CC in diagnostic assays of body fluids or biopsied tissues to detect
 CC expression levels of MCPP. MCPP cDNA may also be useful for
 CC treatment of disorders such as asthma, rheumatoid arthritis, NIDDM
 CC or cancer of the breast or bladder. Human MCPP protein can be used to
 CC identify agonists, antagonists or inhibitors to modulate the activity of
 CC MCPP in allergic responses or autoimmune diseases such as AIDS.

SO Sequence 109 AA;

Query Match 100.0%; Score 386; DB 19; Length 109;
 Best Local Similarity 100.0%; Pred. No. 9.2e-39;
 Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VSIPITCCFNVINRKIPIDRLSEYTRITNIOCPKEAVIFKTRGKVCADPKERVRDSM 60

Db |||||
 38 vsipitccfnvinrkikiprlslyrltnlqcpkeavifktrgkvcadpkervrds 97
 QY 61 KHLDOIIFONLKP 72
 |||||
 Db 98 khlldqifgnlkp 109

RESULT 7

AAW07234
 ID AAW07234 standard; Protein: 71 AA.
 AC AAW07234;

06-JUL-1999 (first entry)

Truncated monocyte chemotactic protein 2 (6-76).

KW Wild type; C-C chemokine; monocyte chemotactic protein 2; MCP2; HIV;
 KW regulated on activation normal T-cell expressed and secreted; RANTES;
 KW truncation; antagonist; medicaments; diagnosis; inflammation; infection;
 KW tumour; angiogenesis; hematopoiesis; autoimmune disease; atherosclerosis;
 KW pulmonary disease; skin disorder.

OS Homo sapiens.

PN EP906954-A1.

PD 07-APR-1999.

PF 29-SEP-1997; 97EP-0116863.

PR 29-SEP-1997; 97EP-0116863.

PA (ISTP) ARS APPLIED RES SYSTEMS HOLDING NV.

PI Proost P, Struyf S, Van Damme J;

DR WPI: 1999-207108/18.

PT New amino-terminally truncated C-C chemokines have antagonistic
 PT activity for treatment of immune, inflammatory and infectious
 PT diseases

PS Claim 4; Fig 1; 29pp; English.

CC This sequence represents a truncated C-C chemokine monocyte chemotactic
 CC protein 2 (MCP2) containing amino acids 6-76 of the mature protein.
 CC The invention relates the generation of amino-terminal truncated C-C
 CC chemokines, having chemokine antagonistic activity. The new chemokines
 CC are useful as medicaments, for diagnosis and/or treatment of diseases
 CC which require antagonistic activity of a chemokine e.g. inflammatory
 CC related diseases, HIV infection, tumours, and angiogenesis and hematopoiesis-
 CC pulmonary diseases, including auto-immune diseases, atherosclerosis,
 CC skin disorders.

SO Sequence 71 AA;

Query Match 99.0%; Score 382; DB 20; Length 71;
 Best Local Similarity 100.0%; Pred. No. 1.7e-38;
 Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 SIPTCCFNVINRKIPIDRLSEYTRITNIOCPKEAVIFKTRGKVCADPKERVRDSM 61
 |||||
 Db 1 sipitccfnvinrkikiprlslyrltnlqcpkeavifktrgkvcadpkervrds 60
 |||||

QY 62 HLDIOIFONLKP 72
 |||||
 Db 61 hldqifgnlkp 71

RESULT 8
AA07238
ID AAY07238 standard; protein: 71 AA.
XX
XX AAY07238;
AC
XX
XX 06-JUL-1999 (first entry)
DT
XX
XX Truncated monocyte chemotactic protein 2 (6-76).
DE
XX
XX Wild type; C-C chemokine; monocyte chemotactic protein 2; MCP2; HIV;
KW regulated on activation normal T-cell expressed and secreted; RANTES;
KW regulation; antagonist; diagnosis; inflammation; infection;
KW tumour; angiogenesis; hematopoiesis; autoimmune disease; atherosclerosis;
KW pulmonary disease; skin disorder.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX EP905241-A1.
PN
XX
XX 10-MAR-1999.
PC
XX
XX 10-MAR-1996; 98EP-0104216.
PF
XX
XX 19-DEC-1997; 97EP-0122471.
PR
XX
XX 29-SEP-1997; 97EP-0116863.
PT
XX
XX (ISMP) ARS APPLIED RES SYSTEMS HOLDING NV.
PA
XX
XX Proost P, Struyf S, Van Damme J;
PI
XX
XX WPI; 1999-206774/18.
DR
XX
XX New amino-terminally truncated C-C chemokines have antagonistic
PT activity for treatment of immune, inflammatory and infectious
PT diseases
PT
XX
XX Claim 4; Fig 1; 29pp; English.
PS
XX
XX This sequence represents a truncated C-C chemokine monocyte chemotactic
CC protein 2 (MCP2) containing amino acids 6-76 of the mature protein.
CC The invention relates to the generation of amino-terminal truncated C-C
CC chemokines, having chemokine antagonistic activity. The new chemokines
CC are useful as medicaments, for diagnosis and/or treatment of diseases
CC which require antagonistic activity of a chemokine e.g. inflammatory
CC diseases, HIV infection, tumours, and angiogenesis- and hematopoiesis-
CC related diseases, including auto-immune diseases, atherosclerosis,
CC pulmonary diseases and skin disorders.
CC
XX
XX Sequence 71 AA;
SQ

Query Match 99.0%; Score 382; DB 20; Length 71;
Best Local Similarity 100.0%; Pred. No. 1.7e-38;
Matches 71; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 SIPTCCFVNIKKIPQRIESTYTRITNIQCPKAVIETKRGKVCADPKRWVDSM 61
DB 1 siptccfvinlkkipqrliesytritniqcpkeavifktrgkvcadpkervwvds 60

QY 62 HLDQIFONLKP 72
DB 61 hldqifgnlkp 71

RESULT 9
AAW26655
ID AAW26655 standard; protein: 109 AA.
XX
XX AAW26655;
AC
XX
XX 16-FEB-1998 (first entry)
DT

XX
XX Human beta-chemokine H1305 (MCP-2).
DE
XX
XX H1305; MCP-2; chemokine; human; chemoattractant; chemotaxis;
KW virus infection; HIV; therapy; wound healing; tumour; antibody.
XX
XX Homo sapiens.
OS
XX
XX WO9725427-A1.
PN
XX
XX 17-JUL-1997.
PD
XX
XX 10-JAN-1997; 97MO-US00379.
PF
XX
XX 12-JAN-1996; 96OS-0586395.
PR
XX
XX (GEM) GENETICS INST INC.
PA
XX
XX Lavallie ER, McCoy JM, Racie LA;
PI
XX
XX WPI; 1997-372866/34.
DR
XX
XX N-PSDB; AAT91023.
DR
XX
XX New human beta-chemokine, H1305 and corresponding DNA - used in the
PT treatment of viral infection, e.g. HIV, and in wound healing
PT
XX
XX Claim 1; Page 12-13; 21pp; English.
PS
XX
XX This protein comprises human beta-chemokine H1305, also known as
CC MCP-2. Its sequence was deduced from a claimed cDNA clone (see
CC AAT91023) isolated from a human peripheral blood mononuclear cell
CC cDNA library. Also claimed are: (1) a host cell, preferably
CC mammalian, transformed with a H1305 polynucleotide operably linked
CC to an expression control sequence; (2) a recombinantly produced
CC H1305 protein; and (3) a composition comprising an antibody which
CC specifically reacts with the H1305 protein. The H1305 protein
CC may be used in a composition for the treatment of a mammalian
CC subject (claimed). It is thought to have chemokine activities and
CC may therefore have an effect on chemotaxis or migration of blood
CC cells. It may be useful for inhibiting viral replication,
CC including replication of HIV, and may also be used for treatment of
CC wounds and to raise monoclonal and polyclonal antibodies which
CC specifically react with H1305. Such antibodies may be used for
CC therapy of certain tumours as they are capable of blocking the
CC ligand binding of the H1305 protein or may promote clearance of
CC the protein from the patient.
CC
XX
XX Sequence 109 AA;
SQ

Query Match 99.0%; Score 382; DB 18; Length 109;
Best Local Similarity 98.6%; Pred. No. 2.8e-38;
Matches 71; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 VSIPITCCFVNIKKIPQRIESTYTRITNIQCPKAVIETKRGKVCADPKRWVDSM 60
DB 38 vsipitccfvinlkkipqrliesytritniqcpkeavifktrgkvcadpkervwvds 97

QY 61 KHDQIFONLKP 72
DB 98 khldqifgnlkp 109

RESULT 10
AAV14223
ID AAV14223 standard; peptide: 77 AA.
XX
XX AAV14223;
AC
XX
XX 29-JUL-1999 (first entry)
DT
XX
XX Chemokine hMCP2.
DE
XX

XX	29-AUG-1995	(first entry)	
DT			
XX			
DE	Chemoattractant MCP-2.		
XX			
KW	Chemoattractant; MCP-2; heparanase; heparin; heparan sulfate;		
KW	arthritis; restenosis; cancer; wound healing.		
XX			
OS	Homo sapiens.		
XX			
PN	W09504158-A.		
XX			
PD	09-FEB-1995.		
XX			
PF	26-JUL-1994; 94WO-0508207.		
XX			
PR	29-JUL-1993; 93US-0099866.		
PR	13-OCT-1993; 93US-0136117.		
XX			
PA	(UPJO) UPJOHN CO.		
XX			
PI	Hoogwerf AJ, Ledbetter SR;		
DR	WPI; 1995-082239/11.		
XX			
PT	Screening for cpds. with anti-heparanase activity - by detecting		
PT	inhibition of heparin or heparan sulphate degradation,		
PT	potentially useful for treating arthritis, restenosis, cancer.		
XX			
PS	Claim 13; Page 53; 60pp; English.		
XX			
CC	Purified heparanases, prepared under reducing conditions and		
CC	activated with transglutaminase, are given in AAR0786-804. Most		
CC	are prepared by reverse transcription of mRNA from activated human		
CC	leukocytes, then cloning of the cDNA into pVL392 baculovirus		
CC	vector, and expression in Sf9 cells in the presence of reduced		
XX	glutathione and dithiothreitol.		
XX			
SQ	Sequence 72 AA;		
Query Match 90.2%; Score 348; DB 16; Length 72;			
Best Local Similarity 94.4%; Pred. No. 2,1e-34;			
Matches 68; Conservative 0; Mismatches 2; Indels 2; Gaps 1.			
QY	1 VSIIITCFEVIINRKIPIDIOLESYRTFTNIQCPKEAVIFKTRKGEVCADPKERWRDSM 60		
DB	3 VSIIITCFEVIINRKIPIDIOLESYRTFTNIQCPKEAVIFKTRKGEVCADPKERWRDSM 60		
QY	61 KHLDFQNLKP 72		
DB	61 KHLDFQNLKP 72		
RESULT 12			
ID	AAI69023 standard; protein; 74 AA.		
XX	AAI69023;		
AC	30-MAY-2000 (first entry)		
XX			
DT			
XX			
DE	Amino acid sequence of chemokine receptor ligand eotaxin.		
XX			
KW	Chemokine receptor; ligand; inflammatory response; immune effector cell;		
KW	secondary tissue damage; central nervous system injury; eotaxin;		
KW	CNS inflammatory disease; neurodegenerative disorder; heart disease;		
KW	inflammatory eye disease; inflammatory bowel disease;		
KW	inflammatory joint disease; inflammatory kidney; renal disease;		
KW	inflammatory lung disease; inflammatory nasal disease;		
KW	inflammatory thyroid disease; thyroiditis; cytokine-regulated cancer.		
XX			
OS	Homo sapiens.		

[illegible]

PR 17-FEB-1995; 9505-0390740.
XX
XX (INCY-) INCYTE PHARM INC.
PA
XX Bandman O, Coleman R, Wilde CG;
PI
XX WPI: 1996-393398/39.
DR N-PSDB; AAT33527.
XX
XX Nucleotide and protein sequences for human PANEC-1 and PANEC-2 -
PT useful in diagnosis and therapy of pancreatic diseases
XX
XX
PS
XX
XX Claim 8; Page 28-29; 43pp; English.
XX
XX The sequences given in AAM0067-68 represent pancreas-derived
CC chemokines, PANEC-1 and PANEC-2. These chemokines are highly expressed
CC and specifically expressed in the pancreas and may therefore be used in
CC diagnostic assays based on chemokine production in cases of
CC inflammation or disease affecting the pancreas. These assays allow
CC the early and accurate diagnosis of pancreatic disorders, and can
CC differentiate between invasive diseases and genetic syndromes.
XX
XX
SQ Sequence 97 AA;

	Query Match	69.2%	Score 267;	DB 17;	Length 97;	
	Best Local Similarity	66.28%	Pred No. 1,7e-24;			
	Matches 47;	Conservative 13;	Mismatches 11;	Indels 0;	Gaps 0;	
OY	2 SIPITCCFNVINRKIPQIRLESTYRITNIQCPEAVIFKTRKGECVCAKDREKRWVRDSMK 61					
	: : : : :					
Dd	27 svptccncnlanrkipqrlresyriltsqkcpkavifktxlakdicadpkkkwvgdsnk 86					
OY	62 HLDQIFONLKP 72					
	:					
Dd	87 yldqkspepkp 97					
	RESULT 14					
AAW14990	ID AAW14990 standard; Protein; 97 AA.					
XX	AAW14990;					
XX	AC					
XX	DT					
XX	01-DEC-1997 (first entry)					
DE	Human eosinocyte CC type chemokine eotaxin.					
KW	Human; eosinocyte; CC type; chemokine; eotaxin; calcium; skin;					
KM	small intestine; agonist; screening; antagonism; inflammation;					
KW	antibody; diagnosis; assay; disorder; asthma; allergy; atopic.					
OS	Homo sapiens.					
PN	MO9712914-A1.					
PD	10-APR-1997.					
PF	01-OCT-1996; 96WO-JP02851.					
PR	28-FEB-1996; 96JP-0041965.					
PR	05-OCT-1995; 95JP-0259067.					
PA	(SHIO) SHIONOGI & CO LTD.					
PI	Harada S, Kitaura M, Nakajima T;					
DR	WPI: 1997-226168/20.					
DR	N-PDB: AAT62944.					
FT	Human CC chemokine (eotaxin) active on eosinocytes - useful for screening for eotaxin (antagonist(s)), e.g. for treating					

PT Inflammation
 PS Claim 2: Pages 27-28; 45pp: Japanese.
 XX
 CC The present sequence is the human eosinophil, CC type
 CC chemokine, eotaxin, which increases calcium flux in human
 CC eosinocytes and is a human analogue of guinea pig eotaxin. The
 CC eotaxin was derived from human small intestine, and is a specific
 CC agonist for human CC type chemokine receptor 3. It may be used to
 CC screen potential agonists and antagonists, which may be useful as
 CC anti-inflammatory. An anti-eotaxin antibody may be used in
 CC diagnostic assays for eotaxin, which is implicated in inflammatory
 CC disorders, e.g. asthma, other allergies and atopic skin
 CC inflammation.
 CC
 SQ Sequence 97 AA:
 Query Match 69.2%; Score 267; DB 18; Length 97;
 Best Local Similarity 66.2%; Pred. No. 1.7e-24;
 Matches 47; Conservative 13; Mismatches 11; Indels 0; Gaps 0;
 QY 2 SIPTCCFNVIKRIPIORLESYRTINIOCPKAEVIFKTRKKEVCADPKERWVDSMK 61
 Db 27 svpttcfnianrkkiprlesyrtitgskcpqkavifkklakdicadpkkkvwgdsnk 86
 QY 62 HLDQIFQNLKP 72
 Db 87 yldgkspkpkp 97
 RESULT 15
 AAM10099
 ID AAM10099 standard; Protein; 97 AA.
 XX
 AC AAM10099:
 DT 30-SEP-1997 (first entry)
 XX
 DE Human eotaxin.
 XX
 KW Human: eotaxin; eosinophil; chemoattractant; stimulation;
 KW accumulation; attraction; chemotaxis; diagnosis; prevention;
 KW treatment; disease; inflammation; allergy; asthma; rhinitis;
 KW hypersensitivity; lung; pneumonia; Loeffler's; syndrome;
 KW interstitial; ILD; idiopathic pulmonary fibrosis;
 KW rheumatoid arthritis; systemic; lupus erythematosus; SLE;
 KW ankylosing spondylitis; sclerosis; Sjorgen's; polymyositis;
 KW dermatomyositis; bowel; anaphylaxis; drug; penicillin;
 KW cephalosporin; insect sting; Crohn's; ulcerative colitis;
 KW spondyloarthritis; scleroderma; psoriasis; dermatosis;
 KW dermatitis; eczema; atopic; urticaria; necrotizing; cutaneous;
 KW vasculitis; myositis; fasciitis; multiple sclerosis;
 KW myasthenia gravis; juvenile onset diabetes; glomerulonephritis;
 KW autoimmune; thyroiditis; Bechet's; graft; rejection;
 KW transplantation; allograft; graft versus host; cancer;
 KW leukocyte infiltration; reperfusion injury; atherosclerosis;
 KW haematologic malignancy; septic; endotoxic; shock;
 KW polymyositis; dermatomyositis; immunosuppression; immunodeficiency;
 KW AIDS; radiation therapy; chemotherapy; autoimmune; corticosteroid;
 KW infection.
 KW
 XX Homo sapiens.
 OS
 XX
 PN MO9700960-A1.
 XX
 PD 09-JAN-1997.
 XX
 XX 21-JUN-1996; 96WO-US10723.
 XX
 XX 23-JUN-1995; 95US-0494093.
 XX
 PA (LEUK-) LEUKOSTE INC.


XX
 PI Mackay C, Newman W, Ponath PD, Qin S, Ringler DJ;
 XX WPI: 1997-087387/08.
 DR N-PSDB: AAT58777.
 DR
 XX
 CC New isolated human eotaxin gene - used to develop prods. for the
 CC diagnosis and treatment of e.g. inflammation, allergies, auto-immune
 CC disease, infections and tumors
 CC
 PS Claim 3: Pages 95-96; 130pp: English.
 XX
 CC The present sequence is human eotaxin (he), an eosinophil
 CC specific chemoattractant capable of stimulating eosinophil
 CC accumulation and/or attracting eosinophils (including chemotaxis).
 CC It can be used to develop products for the diagnosis, prevention or
 CC treatment of he associated diseases or conditions. The products can
 CC be used to treat inflammatory or allergic diseases and conditions,
 CC including respiratory allergic diseases (e.g. asthma, allergic
 CC rhinitis, hypersensitivity lung diseases or pneumonitis,
 CC eosinophilic pneumonia, interstitial lung diseases (ILD) such as
 CC idiopathic pulmonary fibrosis or ILD associated with rheumatoid
 CC arthritis, systemic lupus erythematosus (SLE), ankylosing
 CC spondylitis, systemic sclerosis, Sjorgen's syndrome, polymyositis
 CC or dermatomyositis), systemic anaphylaxis or hypersensitivity
 CC responses, drug allergies (e.g. to penicillin and cephalosporins),
 CC insect sting allergies, inflammatory bowel diseases (e.g. Crohn's
 CC disease and ulcerative colitis), spondyloarthritis, psoriasis,
 CC scleroderma, psoriasis and inflammatory dermatoses (e.g.
 CC dermatitis, eczema, atopic dermatitis, allergic contact dermatitis,
 CC urticaria and necrotizing, cutaneous and hypersensitivity
 CC vasculitis), eosinophilic myositis and fasciitis, multiple
 CC sclerosis, SLE, myasthenia gravis, juvenile onset diabetes,
 CC glomerulonephritis, autoimmune thyroiditis, Bechet's disease, graft
 CC rejection (e.g. in transplantation) including allograft rejection or
 CC graft versus host disease and cancers with leukocyte infiltration
 CC of the skin or organs. The products can also be used to treat other
 CC diseases or conditions requiring the inhibition of undesirable
 CC inflammatory responses, including reperfusion injury,
 CC atherosclerosis, certain haematologic malignancies, cytokine
 CC induced toxicity (e.g. septic or endotoxic shock), polymyositis,
 CC dermatomyositis, immunosuppression (e.g. in individuals with
 CC immunodeficiency syndromes such as AIDS, undergoing radiation
 CC therapy, chemotherapy, therapy for autoimmune disease or other drug
 CC therapy, such as corticosteroid therapy, which causes
 CC immunosuppression), immunosuppression due to (e.g. congenital)
 CC deficiency (e.g. in eotaxin) or infectious diseases such as parasitic
 CC diseases.
 CC Degenerate primers based on the guinea pig eotaxin amino acid
 CC sequence were used for the reverse transcriptase polymerase chain
 CC reaction (RT-PCR) amplification of RNA isolated from inflamed
 CC eosinophilic lung tissue obtained from Balb/c mice sensitised to
 CC ovalbumin. The amplification product was used as a probe to screen
 CC a human genomic library in vector EMBL3 SP6/77 to obtain the he
 CC gene.
 CC
 XX
 SQ Sequence 97 AA:
 Query Match 69.2%; Score 267; DB 18; Length 97;
 Best Local Similarity 66.2%; Pred. No. 1.7e-24;
 Matches 47; Conservative 13; Mismatches 11; Indels 0; Gaps 0;
 QY 2 SIPTCCFNVIKRIPIORLESYRTINIOCPKAEVIFKTRKKEVCADPKERWVDSMK 61
 Db 27 svpttcfnianrkkiprlesyrtitgskcpqkavifkklakdicadpkkkvwgdsnk 86
 QY 62 HLDQIFQNLKP 72
 Db 87 yldgkspkpkp 97

Mon Aug 12 10:36:57 2002

us-09-537-859b-2_copy_28_99.rag

Page 9

Search completed: August 12, 2002, 10:47:58
Job time: 59 sec



GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 12, 2002, 10:46:59 ; Search time 13.03 Seconds
(without alignments)
134,969 Million cell updates/sec

Title: US-09-537-859B-2_COPY_28_99

Perfect score: 386
Sequence: 1 VSIPITCCFNVIRKRIPIQR.....ERWVRDSMKHLDQIFQNLKP 72

Scoring table:
BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 231628 seqs, 24425594 residues

TC: number of hits satisfying chosen parameters: 231628

Minimum DB seq length: 0.

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents-AA:*
1: /cgn2_6/ptodata/2/1aa/5A.COMB.pep:*
2: /cgn2_6/ptodata/2/1aa/5B.COMB.pep:*
3: /cgn2_6/ptodata/2/1aa/6A.COMB.pep:*
4: /cgn2_6/ptodata/2/1aa/6B.COMB.pep:*
5: /cgn2_6/ptodata/2/1aa/PCIOS.COMB.pep:*
6: /cgn2_6/ptodata/2/1aa/Backfill1est1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	386	100.0	74	2	US-08-615-232A-6
2	386	100.0	74	3	US-08-470-323-6
3	386	100.0	76	1	US-08-480-449-20
4	386	100.0	76	2	US-08-716-188-3
5	386	100.0	76	2	US-08-660-542-20
6	386	100.0	77	4	US-08-479-603-20
7	386	100.0	77	1	US-08-347-492B-9
8	386	100.0	77	2	US-08-421-144A-6
9	386	100.0	77	2	US-08-798-143-9
10	386	100.0	77	4	US-08-613-822-20
11	255.5	66.2	96	4	US-09-330-637-44
12	249	64.5	76	1	US-07-956-862A-1
13	249	64.5	76	1	US-08-250-958-1
14	249	64.5	76	1	US-08-335-659-1
15	249	64.5	76	2	US-08-716-188-2
16	249	64.5	76	2	US-08-615-232A-5
17	249	64.5	76	3	US-08-470-323-5
18	249	64.5	78	1	US-08-330-163-12
19	249	64.5	78	1	US-08-482-111-12
20	249	64.5	78	5	PCT-US95-00605-1
21	249	64.5	79	1	US-08-127-499A-35
22	249	64.5	99	1	US-08-482-847-35
23	249	64.5	99	1	US-08-347-492B-8
24	249	64.5	99	1	US-08-480-449-19
25	249	64.5	99	2	US-08-479-126B-5
26	249	64.5	99	2	US-08-421-144A-5
27	249	64.5	99	2	US-08-726-830A-5

28	249	64.5	99	2	US-08-660-542-19	Sequence 19, Appl
29	249	64.5	99	2	US-08-798-143-8	Sequence 8, Appl
30	249	64.5	99	3	US-07-927-391-24	Sequence 24, Appl
31	249	64.5	99	3	US-08-995-156A-5	Sequence 5, Appl
32	249	64.5	99	3	US-09-044-856A-5	Sequence 5, Appl
33	249	64.5	99	3	US-09-044-855A-5	Sequence 5, Appl
34	249	64.5	99	4	US-08-679-493A-152	Sequence 152, App
35	249	64.5	99	4	US-08-479-603-19	Sequence 19, Appl
36	249	64.5	99	5	PCT-US96-10087-5	Sequence 5, Appl
37	249	64.5	99	6	5212073-2	Patent No. 5212073
38	241	62.4	104	4	US-08-744-419-2	Sequence 19, Appl
39	234	60.6	76	4	US-08-613-822-19	Sequence 18, Appl
40	234	60.6	99	1	US-08-480-449-18	Sequence 18, Appl
41	234	60.6	99	2	US-08-660-542-18	Sequence 18, Appl
42	234	60.6	99	4	US-08-613-822-18	Sequence 18, Appl
43	234	60.6	99	4	US-08-479-603-18	Sequence 7, Appl
44	234	60.6	109	2	US-08-421-144A-7	Sequence 16, Appl
45	234	60.6	109	3	US-07-927-391-16	

ALIGNMENTS

RESULT 1
US-08-615-232A-6
Sequence 6, Application US/08615232A
Patent No. 5993814
GENERAL INFORMATION:
APPLICANT: WILLIAMS, TIMOTHY J.
APPLICANT: JOSE, PETER J.
APPLICANT: GRIFFITHS-JOHNSON, DAVID A.
APPLICANT: HSUAN, JOHN J.
TITLE OF INVENTION: CHEMOTACTIC CYTOKINE
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESSES:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/615, 232A
FILING DATE: 13-AUG-1996
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9318984
FILING DATE: 14-SEP-1993
APPLICATION NUMBER: GB 9408602
FILING DATE: 29-APR-1994
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 550-32
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 74 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-615-232A-6

Query Match 100.0%, Score 386, DB 2, Length 74;

Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VSIPITCCFNVINRKIPIDRLSESYRTITNIOCPKEAVIFKTRGKGVCAADPKERWVRDSM 60
DB 3 VSIPITCCFNVINRKIPIDRLSESYRTITNIOCPKEAVIFKTRGKGVCAADPKERWVRDSM 62

QY 61 KHLDOIIONLKP 72
DB 63 KHLDOIIONLKP 74

RESULT 2

US-08-470-323-6
Sequence 6, Application US/08470323A
Patent No. 6031080

GENERAL INFORMATION:
APPLICANT: WILLIAMS, TIMOTHY J.

APPLICANT: JOSE, PETER J.
APPLICANT: GRIFFITHS-JOHNSON, DAVID A.

APPLICANT: HSUAN, JOHN J.

TITLE OF INVENTION: CHEMOTACTIC CYTOKINE

FILE REFERENCE: 550-33

CURRENT APPLICATION NUMBER: US/08/470,323A

EARLIER FILING DATE: 1995-06-06

EARLIER APPLICATION NUMBER: PCT/GB94/02006

EARLIER FILING DATE: 1994-09-14

EARLIER APPLICATION NUMBER: GB 9318984.3

EARLIER FILING DATE: 1993-09-14

EARLIER APPLICATION NUMBER: GB 94086902.2

NUMBER OF SEQ ID NOS: 11

SEQ ID NO: 6

LENGTH: 74

TYPE: PRT

ORGANISM: human

US-08-470-323-6

Query Match 100.0%; Score 386; DB 3; Length 74;

Best Local Similarity 100.0%; Pred. No. 1.3e-43;

Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VSIPITCCFNVINRKIPIDRLSESYRTITNIOCPKEAVIFKTRGKGVCAADPKERWVRDSM 60
DB 3 VSIPITCCFNVINRKIPIDRLSESYRTITNIOCPKEAVIFKTRGKGVCAADPKERWVRDSM 62

QY 61 KHLDOIIONLKP 72
DB 63 KHLDOIIONLKP 74

RESULT 3

US-08-480-449-20
Sequence 20, Application US/08480449
Patent No. 5686927

GENERAL INFORMATION:
APPLICANT: Godiska, Ronald

APPLICANT: Gray, Patrick W.

TITLE OF INVENTION: MACROPHAGE DERIVED CHEMOKINE

NUMBER OF SEQUENCES: 24

CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

CITY: Chicago
STATE: Illinois

COUNTRY: United States of America

ZIP: 60606-6402

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/480,449

FILING DATE:

CLASSIFICATION: 530

ATTORNEY/AGENT INFORMATION:

NAME: Gass, David A.

REGISTRATION NUMBER: 38,153

REFERENCE/DOCKET NUMBER: 27866/32779

TELECOMMUNICATION INFORMATION:

TELEPHONE: 312/474-6300

TELEFAX: 312/474-0448

TELEX: 25-3856

INFORMATION FOR SEQ ID NO: 20:

SEQUENCE CHARACTERISTICS:

LENGTH: 76 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

FEATURE:

NAME/KEY: misc.feature

OTHER INFORMATION: "Hu MCP-2"

US-08-480-449-20

Query Match 100.0%; Score 386; DB 1; Length 76;

Best Local Similarity 100.0%; Pred. No. 1.3e-43;

Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VSIPITCCFNVINRKIPIDRLSESYRTITNIOCPKEAVIFKTRGKGVCAADPKERWVRDSM 60
DB 5 VSIPITCCFNVINRKIPIDRLSESYRTITNIOCPKEAVIFKTRGKGVCAADPKERWVRDSM 64

QY 61 KHLDOIIONLKP 72
DB 65 KHLDOIIONLKP 76

RESULT 4

US-08-716-188-3
Sequence 3, Application US/08716188
Patent No. 5908829

GENERAL INFORMATION:
APPLICANT: KELLY, RODNEY W

TITLE OF INVENTION: USE OF MCP-1 FOR INDUCING RIPENING OF

NUMBER OF SEQUENCES: 7

CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.

STREET: 1100 NORTH GLEBE ROAD

CITY: ARLINGTON

STATE: VA

COUNTRY: USA

ZIP: 22201

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/716,188

FILING DATE: 30-SEP-1996

CLASSIFICATION: 530

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/GB95/00733

FILING DATE: 31-MAR-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: GB 9406463.1

FILING DATE: 31-MAR-1994

ATTORNEY/AGENT INFORMATION:

NAME: SADOFF, B.J.

REGISTRATION NUMBER: 36,663

REFERENCE/DOCKET NUMBER: 117-219

TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-816-4091
TELEFAX: 703-816-4100
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 76 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-716-188-3

Query Match 100.0%; Score 386; DB 2; Length 76;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 VSIPITCCFNVINRKIPIDQRLSESYTRITNIQCPKEAVIFKTKRGKVCADPKERWVRDSM 60
DB 5 VSIPITCCFNVINRKIPIDQRLSESYTRITNIQCPKEAVIFKTKRGKVCADPKERWVRDSM 64

OY 61 KHLDFQNLKP 72
DB 65 KHLDFQNLKP 76

RESULT 5
US-08-660-542-20
Sequence 20, Application US/08660542
Patent No. 5932703
GENERAL INFORMATION:
APPLICANT: Godiska, Ronald
APPLICANT: Gray, Patrick W.
TITLE OF INVENTION: MACROPHAGE DERIVED CHEMOKINE AND CHEMOKINE
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentln Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/660,542
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/558,658
FILING DATE: 16-NOV-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/479,620
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Gass, David A.
REGISTRATION NUMBER: 38,153
REFERENCE/DOCKET NUMBER: 27866/33318
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 76 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide

FEATURE:
NAME/KEY: misc-feature
OTHER INFORMATION: "Hu MCP-2"
US-08-660-542-20

Query Match 100.0%; Score 386; DB 2; Length 76;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 VSIPITCCFNVINRKIPIDQRLSESYTRITNIQCPKEAVIFKTKRGKVCADPKERWVRDSM 60
DB 5 VSIPITCCFNVINRKIPIDQRLSESYTRITNIQCPKEAVIFKTKRGKVCADPKERWVRDSM 64

OY 61 KHLDFQNLKP 72
DB 65 KHLDFQNLKP 76

RESULT 6
US-08-479-603-20
Sequence 20, Application US/08479603
Patent No. 6320023
GENERAL INFORMATION:
APPLICANT: Godiska, Ronald
APPLICANT: Gray, Patrick W.
TITLE OF INVENTION: MACROPHAGE DERIVED CHEMOKINE
NUMBER OF SEQUENCES: 24
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentln Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/479,603
FILING DATE:
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Gass, David A.
REGISTRATION NUMBER: 38,153
REFERENCE/DOCKET NUMBER: 27866/32780
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 76 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
NAME/KEY: misc-feature
OTHER INFORMATION: "Hu MCP-2"
US-08-479-603-20

Query Match 100.0%; Score 386; DB 4; Length 76;
Best Local Similarity 100.0%; Pred. No. 1.3e-43;
Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 VSIPITCCFNVINRKIPIDQRLSESYTRITNIQCPKEAVIFKTKRGKVCADPKERWVRDSM 60
DB 5 VSIPITCCFNVINRKIPIDQRLSESYTRITNIQCPKEAVIFKTKRGKVCADPKERWVRDSM 64

QY 61 KHLDOIFONLKP 72
DB 65 KHLDOIFONLKP 76

RESULT 7

US-08-347-492B-9
Sequence 9, Application US/08347492B
Patent No. 5602008
GENERAL INFORMATION:
APPLICANT: Wilde, Craig G.
APPLICANT: Hawkins, Phillip R.
APPLICANT: Bandman, Olga
APPLICANT: Sellhammer, Jeffrey J.
TITLE OF INVENTION: EXPRESSED CHEMOKINES, THEIR
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: U.S.
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: diskette
COMPUTER: IBM compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/347,492B
FILING DATE: 29-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/303,241
FILING DATE: 07-SEP-1994
APPLICATION NUMBER: 08/320,011
FILING DATE: 05-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Luther, Barbara J.
REGISTRATION NUMBER: 33,954
REFERENCE/DOCKET NUMBER: PF-0024
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-852-0195
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 77 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
LIBRARY: GENBANK
CLONE: GI 126829
US-08-347-492B-9

Query Match 100.0%; Score 386; DB 1; Length 77;
Best Local Similarity 100.0%; Pred. No. 1,4e-43;
Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VSIPITCCFNVINRKIPQRLSEYTRITNIOCPKEAVIFKTRGKVCADPKRRVWRDSM 60
DB 6 VSIPITCCFNVINRKIPQRLSEYTRITNIOCPKEAVIFKTRGKVCADPKRRVWRDSM 65
QY 61 KHLDOIFONLKP 72
DB 66 KHLDOIFONLKP 77

RESULT 8
US-08-421-144A-6
Sequence 6, Application US/08421144A

Patent No. 5874211
GENERAL INFORMATION:
APPLICANT: BANDMAN, OLGA
APPLICANT: COLEMAN, ROGER
APPLICANT: STUART, SUSAN G.
TITLE OF INVENTION: NEW CHEMOKINE EXPRESSED IN EOSINOPHILS
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: INCYTE PHARMACEUTICALS, INC.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/421,144A
FILING DATE: 13-APR-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Luther, Barbara J.
REGISTRATION NUMBER: 33954
REFERENCE/DOCKET NUMBER: PF-0031 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-852-0195
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 77 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-421-144A-6

Query Match 100.0%; Score 386; DB 2; Length 77;
Best Local Similarity 100.0%; Pred. No. 1,4e-43;
Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VSIPITCCFNVINRKIPQRLSEYTRITNIOCPKEAVIFKTRGKVCADPKRRVWRDSM 60
DB 6 VSIPITCCFNVINRKIPQRLSEYTRITNIOCPKEAVIFKTRGKVCADPKRRVWRDSM 65
QY 61 KHLDOIFONLKP 72
DB 66 KHLDOIFONLKP 77

RESULT 9

US-08-798-143-9
Sequence 9, Application US/08798143
Patent No. 5936068
GENERAL INFORMATION:
APPLICANT: Wilde, Craig G.
APPLICANT: Hawkins, Phillip R.
APPLICANT: Bandman, Olga
APPLICANT: Sellhammer, Jeffrey J.
TITLE OF INVENTION: EXPRESSED CHEMOKINES, THEIR
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: U.S.
ZIP: 94304
COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/798,143
FILING DATE: 10-FEB-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/347,492
FILING DATE: 29-NOV-1994
APPLICATION NUMBER: 08/303,241
FILING DATE: 07-SEP-1994
APPLICATION NUMBER: 08/320,011
FILING DATE: 03-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Luther, Barbara J
REGISTRATION NUMBER: 33,954
REFERENCE/DOCKET NUMBER: PF-0024
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-852-0195
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 77 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
LIBRARY: GENBANK
CLONE: GI 126829
US-08-798-143-9

Query Match 100.0%; Score 386; DB 2; Length 77;
Best Local Similarity 100.0%; Pred. No. 1.4e-43;
Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VSPIPCFNVINRKIPRIORLESTYRITNIOCPKAVIFKTRKRGVCADPKRWVDSM 60
DB 6 VSPTTCFNVINRKIPRIORLESTYRITNIOCPKAVIFKTRKRGVCADPKRWVDSM 65

QY 61 KHLDFONLKP 72
DB 66 KHLDFONLKP 77

RESULT 10
US-08-613-822-20
Sequence 20, Application US/08613822
Patent No. 6174995
GENERAL INFORMATION:
APPLICANT: Li, Haodong
TITLE OF INVENTION: Human Chemokine Polypeptides
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Human Genome Sciences, Inc.
STREET: 9410 Key West Avenue
CITY: Rockville
STATE: MD
COUNTRY: USA
ZIP: 20850
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/613,822
FILING DATE: 23-FEB-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:

NAME: Millstein, Larry S
REGISTRATION NUMBER: 34,679
TELECOMMUNICATION INFORMATION:
TELEPHONE: 301-309-8504
TELEFAX: 301-309-8512
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 74 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-613-822-20

Query Match 69.2%; Score 267; DB 4; Length 74;
Best Local Similarity 66.2%; Pred. No. 5.4e-28;
Matches 47; Conservative 13; Mismatches 11; Indels 0; Gaps 0;

QY 2 SIPITCCFNVINRKIPRIORLESTYRITNIOCPKAVIFKTRKRGVCADPKRWVDSM 61
DB 4 SVPTTCFNVINRKIPRIORLESTYRITNIOCPKAVIFKTRKRGVCADPKRWVDSM 63

QY 62 HLDQIFONLKP 72
DB 64 YLDQKSPTRKP 74

RESULT 11
US-09-230-637-44
Sequence 44, Application US/09230637
Patent No. 6264958
GENERAL INFORMATION:
APPLICANT: Hayward, Gary
APPLICANT: Nicholas, John
APPLICANT: Hardwick, J. Marie
TITLE OF INVENTION: No. 6264958el Genes of Kaposi's Sarcoma
FILE REFERENCE: 1107,78372
CURRENT APPLICATION NUMBER: US/09/230,637
CURRENT FILING DATE: 1999-11-23
PRIOR APPLICATION NUMBER: 60/022,591
PRIOR FILING DATE: 1996-07-25
PRIOR APPLICATION NUMBER: PCT US 97/12931
PRIOR FILING DATE: 1997-07-24
NUMBER OF SEQ ID NOS: 62
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 44
LENGTH: 96
TYPE: PRT
ORGANISM: Homo sapiens
US-09-230-637-44

Query Match 66.2%; Score 255.5; DB 4; Length 96;
Best Local Similarity 66.2%; Pred. No. 2.4e-26;
Matches 47; Conservative 12; Mismatches 11; Indels 1; Gaps 1;

QY 2 SIPITCCFNVINRKIPRIORLESTYRITNIOCPKAVIFKTRKRGVCADPKRWVDSM 61
DB 27 SVPTTCFNVINRKIPRIORLESTYRITNIOCPKAVIFKTRKRGVCADPKRWVDSM 85

QY 62 HLDQIFONLKP 72
DB 86 YLDQKSPTRKP 96

RESULT 12
US-07-956-862A-1
Sequence 1, Application US/07956862A
Patent No. 5413778
GENERAL INFORMATION:

APPLICANT: KUNKEL, STEVEN L.
 APPLICANT: LYLE, LEON R.
 APPLICANT: STRIETER, ROBERT M.
 TITLE OF INVENTION: LABELLED MONOCYTE CHEMOATTRACTANT
 TITLE OF INVENTION: PROTEIN MATERIAL AND MEDICAL USES
 TITLE OF INVENTION: THEREOF
 NUMBER OF SEQUENCES: 1
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Rothwell, Figg, Ernst & Kurz
 STREET: Suite 701-E, 555 Thirteenth St., N.W
 CITY: Washington
 STATE: D. C.
 COUNTRY: U.S.A.
 ZIP: 20004
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/07/956,862A
 FILING DATE: 05-OCT-1992
 CLASSIFICATION: 424
 ATTORNEY/AGENT INFORMATION:
 NAME: REPPER, GEORGE R.
 REGISTRATION NUMBER: 31,414
 REFERENCE/DOCKET NUMBER: 1670-197A
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202)783-6040
 TELEFAX: (202)783-6031
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 76 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 HYPOTHEICAL: NO
 FRAGMENT TYPE: N-terminal
 US-07-956-862A-1

```

Query Match 64.5%; Score 249; DB 1; Length 76;
Best Local Similarity 62.0%; Pred. No. 1,3e-25;
Matches 44; Conservative 12; Mismatches 15; Indels 0; Gaps 0.

0.
1
2.
3.
4.
5
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.

Db 65 DHDKQTOFVK 75

RESULT 13
US-08-250-958-1
; Sequence 1, Application US/08250958
; Patent No. 5571713
; GENERAL INFORMATION:
APPLICANT: LYLE, LEON R.
APPLICANT: KUNKEL, STEVEN L.
APPLICANT: STRIERER, ROBERT M.
TITLE OF INVENTION: THERAPEUTIC TREATMENT FOR INHIBITING
TITLE OF INVENTION: VASCULAR RESTENOSIS
NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Rothwell, Figg, Ernst & Kurz
STREET: Suite 701-E, 555 Thirteenth St., N.W
City: Washington
STATE: D. C.
COUNTRY: U.S.A.
ZIP: 20004
COMPUTER READABLE FORM:

```

```

MEDIAN TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/08/250,958
  FILING DATE: 27-MAY-1994
  CLASSIFICATION: 514
  PRIOR APPLICATION DATA:
    APPLICATION NUMBER: 07/965,678
    FILING DATE: 22-OCT-1992
  ATTORNEY/AGENT INFORMATION:
    NAME: WALKER, Barbara W
    REGISTRATION NUMBER: 35,400
    REFERENCE/DOCKET NUMBER: 2077-206A
  TELECOMMUNICATION INFORMATION:
    TELEPHONE: (202)783-6040
    TELEFAX: (202)783-6031
  INFORMATION FOR SEQ ID NO: 1:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 76 amino acids
      TYPE: amino acid
      STRANDEDNESS:
        TOPOLOGY: linear
      MOLECULE TYPE: peptide
      HYPOTHETICAL: NO
      FRAGMENT TYPE: N-terminal
US-08-250-958-1

```

```

Query Match Similarity 64.5%; Score 249; DB 1; Length 76;
Best Local Similarity 62.0%; Pred. No. 1,3e-25;
Matches 44; Conservative 12; Mismatches 15; Indels 0; Gaps 0;

QY 1 VSPITTCENVYTRKIPDIOLSYPTNTNIOCPKEAVLFFKTKRGEKVCAPKERNWDSM 60
   5 :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 5 INAVPTCCICFNTNRKISVGRSLASRYRITSRCKPKAVFTKTIYAKKICADPKRWQDSM 64
   1 :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
QY 61 KHLDDIFQNLK 71
   1 :|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 65 DHLDDQDTLPK 75

```

RESULT 14
US-08-235-659-1
Sequence 1, Application US/08235659
Patent No. 5605671
GENERAL INFORMATION:
APPLICANT: Lyle, Leon R.
APPLICANT: Kunkel, Steven L.
APPLICANT: Stiebler, Robert M.
TITLE OF INVENTION: LABELLED CHEMOKINE MATERIALS AND
TITLE OF INVENTION: MEDICAL USES THEREOF
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: Rothwell, Figg, Ernst & Kurtz
STREET: Suite 701-E, 555 Thirteenth St., N.W
CITY: Washington
STATE: D. C.
COUNTRY: U.S.A.
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/235,659
FILING DATE: 29-APR-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/956,862
FILING DATE: 05-OCT-1992

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/956,863
 FILING DATE: 05-OCT-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: WALKER, Barbara W.
 REGISTRATION NUMBER: 35,400
 REFERENCE/DOCKET NUMBER: 2077-205A
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202)783-6040
 TELEFAX: (202)783-6031
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 76 amino acids
 TYPE: amino acid
 STRANDEDNESS: not relevant
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 FRAGMENT TYPE: N-terminal
 US-08-235-659-1

Match 64.5%; Score 249; DB 1; Length 76;
 Best Local Similarity: 62.0%; Pred. No. 1.3e-25;
 Matches 44; Conservative 12; Mismatches 15; Indels 0; Gaps 0;
 QY 1 VSIPITCCENVINRKIPIDRLESYTRITNIOCPKEAVIFKTKRGKVCADPKERWRDSM 60
 DB 5 INAPVTCGYNFTNRKISVQRLASTYRITSSCKPEAVIFKTIYAKETICADPKQKWQDSM 64
 QY 61 KHLDOIPONLK 71
 DB 65 DHLDKQOTQPK 75

RESULT 15
 US-08-716-188-2
 Sequence 2, Application us/08716188
 Patent No. 5908829
 GENERAL INFORMATION:
 APPLICANT: KELLY, RODNEY W
 TITLE OF INVENTION: USE OF MCP-1 FOR INDUCING RIPEINING OF
 NUMBER OF SEQUENCES: 7
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: NIXON & VANDERHAYE P.C.
 STREET: 1100 NORTH GLEBE ROAD
 CITY: ARLINGTON
 STATE: VA
 COUNTRY: USA
 ZIP: 22201
 COMPUTER READABLE FORM:
 MEDIUM TYPE: floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/716,188
 FILING DATE: 30-SEP-1996
 CLASSIFICATION: 530
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: PCT/GB95/00733
 FILING DATE: 31-MAR-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: GB 9406463.1
 FILING DATE: 31-MAR-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: SADOFF, B. J.
 REGISTRATION NUMBER: 36,663
 REFERENCE/DOCKET NUMBER: 117-219
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 703-816-4091
 TELEFAX: 703-816-4100
 INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:
 LENGTH: 76 amino acids
 TYPE: amino acid
 STRANDEDNESS:
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-716-188-2

Query Match 64.5%; Score 249; DB 2; Length 76;
 Best Local Similarity: 62.0%; Pred. No. 1.3e-25;
 Matches 44; Conservative 12; Mismatches 15; Indels 0; Gaps 0;
 QY 1 VSIPITCCENVINRKIPIDRLESYTRITNIOCPKEAVIFKTKRGKVCADPKERWRDSM 60
 DB 5 INAPVTCGYNFTNRKISVQRLASTYRITSSCKPEAVIFKTIYAKETICADPKQKWQDSM 64
 QY 61 KHLDOIPONLK 71
 DB 65 DHLDKQOTQPK 75

Search completed: August 12, 2002, 10:47:21
 Job time: 22 sec

